{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T07:08:09Z","timestamp":1706080089408},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Central aortic blood pressure (CBP) and CBP-derived parameters are independent predictors of cardiovascular risk. Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors plus calcium channel blockers are the recommended first-line treatments in hypertensive diabetic patients; however, the effect in reducing CBP when a dose is skipped has not been established yet. The aim was to determine whether the fixed-dose combination of olmesartan\/amlodipine (OLM\/AML) provides equal efficacy and safety as the perindopril\/AML (PER\/AML) combination in reducing CBP, augmentation index (AIx), and pulse wave velocity (PWV) when a drug dose is missed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>In this noninferiority, randomized, double-blind, double-dummy parallel group, controlled design trial, 88 patients received either OLM 20\u201340mg\/AML 5\u201310mg (41 patients) or PER 4\u20138mg\/AML 5\u201310mg (47 patients) for 24 weeks. The main endpoint was the aortic systolic BP (SBP) after 24 weeks of treatment at 48 hours from the last administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The OLM\/AML combination reached the noninferiority criteria in reducing central systolic BP after 24 weeks of treatment and after the missed dose, compared to the PER\/AML combination (\u221217 and \u22128mm Hg, respectively). Peripheral BP, AIx, and PWV were significantly lower in both groups after 24 weeks of treatment and 48 hours after the missed dose, observing a trend to a greater reduction in CBP-derived parameters in the OLM\/AML group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The OLM\/AML combination is safe, well tolerated, and not inferior to the combination of PER\/AML in lowering CBP and CBP-derived parameters in diabetic patients. OLM\/AML provides longer-lasting efficacy in terms of CBP reduction compared to PER\/AML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpw033","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T02:57:46Z","timestamp":1464145066000},"page":"1055-1062","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Study of the Efficacy of Olmesartan\/Amlodipine vs. Perindopril\/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes"],"prefix":"10.1093","volume":"29","author":[{"given":"Josep","family":"Redon","sequence":"first","affiliation":[{"name":"Hypertension Clinic, Department of Internal Medicine, Clinical Hospital of Valencia 1 , , , Valencia , Spain ;"},{"name":"INCLIVA 1 , , , Valencia , Spain ;"},{"name":"University of Valencia 1 , , , Valencia , Spain ;"},{"name":"CIBERObn, Instituto de Salud Carlos III 2 , Madrid , Spain ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Pichler","sequence":"additional","affiliation":[{"name":"Hypertension Clinic, Department of Internal Medicine, Clinical Hospital of Valencia 1 , , , Valencia , Spain ;"},{"name":"INCLIVA 1 , , , Valencia , Spain ;"},{"name":"University of Valencia 1 , , , Valencia , Spain ;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"2024012405585142000_CIT0001","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.cjca.2014.03.010","article-title":"Central blood pressure as an index of antihypertensive control: determinants and potential value","volume":"30","author":"Trudeau","year":"2014","journal-title":"Can J Cardiol"},{"key":"2024012405585142000_CIT0002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/2012.jama.10503","article-title":"Aortic stiffness, blood pressure progression, and incident hypertension","volume":"308","author":"Kaess","year":"2012","journal-title":"JAMA"},{"key":"2024012405585142000_CIT0003","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1097\/HJH.0000000000000249","article-title":"Estimation of central aortic blood pressure: a systematic meta-analysis of available techniques","volume":"32","author":"Narayan","year":"2014","journal-title":"J Hypertens"},{"key":"2024012405585142000_CIT0004","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1258\/vasc.2011.ra0054","article-title":"Pulse wave velocity and the non-invasive methods used to assess it: Complior, SphygmoCor, Arteriograph and Vicorder","volume":"20","author":"Davies","year":"2012","journal-title":"Vascular"},{"key":"2024012405585142000_CIT0005","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1097\/HJH.0000000000000631","article-title":"Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment","volume":"9","author":"Pichler","year":"2015","journal-title":"J Hypertens"},{"key":"2024012405585142000_CIT0006","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.109.886655","article-title":"Arterial stiffness and cardiovascular events: the Framingham Heart Study","volume":"121","author":"Mitchell","year":"2010","journal-title":"Circulation"},{"key":"2024012405585142000_CIT0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"key":"2024012405585142000_CIT0008","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1586\/erc.12.59","article-title":"Treatment of hypertension in diabetes: what is the best therapeutic option?","volume":"10","author":"Aksnes","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2024012405585142000_CIT0009","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"2024012405585142000_CIT0010","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/HYPERTENSIONAHA.108.111674","article-title":"Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering","volume":"51","author":"Karalliedde","year":"2008","journal-title":"Hypertension"},{"key":"2024012405585142000_CIT0011","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/1470320315573681","article-title":"Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"16","author":"Gismondi","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2024012405585142000_CIT0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.HYP.0000224283.76347.8c","article-title":"Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives","volume":"48","author":"Tropeano","year":"2006","journal-title":"Hypertension"},{"key":"2024012405585142000_CIT0013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.jhh.1002025","article-title":"Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension","volume":"20","author":"Spoelstra-de Man","year":"2006","journal-title":"J Hum Hypertens"},{"key":"2024012405585142000_CIT0014","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2337\/dc12-0176","article-title":"Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study","volume":"35","author":"Johansen","year":"2012","journal-title":"Diabetes Care"},{"key":"2024012405585142000_CIT0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3111\/13696998.2011.596873","article-title":"Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan\/amlodipine single-pill combination versus angiotensin receptor blocker\/calcium channel blocker free-combination therapy","volume":"14","author":"Baser","year":"2011","journal-title":"J Med Econ"},{"key":"2024012405585142000_CIT0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/HJH.0000000000000793","article-title":"Comparative study of the efficacy of olmesartan\/amlodipine vs. perindopril\/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes","volume":"34","author":"Redon","year":"2016","journal-title":"J Hypertens"},{"key":"2024012405585142000_CIT0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clinthera.2008.01.012","article-title":"Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial","volume":"30","author":"Hermida","year":"2008","journal-title":"Clin Ther"},{"key":"2024012405585142000_CIT0018","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0895-7061(99)00142-9","article-title":"A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study","volume":"12","author":"Lacourci\u00e8re","year":"1999","journal-title":"Am J Hypertens"},{"key":"2024012405585142000_CIT0019","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amjhyper.2004.02.016","article-title":"Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period","volume":"17","author":"White","year":"2004","journal-title":"Am J Hypertens"},{"key":"2024012405585142000_CIT0020","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1093\/eurheartj\/ehu293","article-title":"Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors","volume":"35","author":"Herbert","year":"2014","journal-title":"Eur Heart J"},{"key":"2024012405585142000_CIT0021","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/eurheartj\/ehq024","article-title":"Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis","volume":"31","author":"Vlachopoulos","year":"2010","journal-title":"Eur Heart J"},{"key":"2024012405585142000_CIT0022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2125.2012.04342.x","article-title":"Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index","volume":"75","author":"Manisty","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2024012405585142000_CIT0023","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2174\/138161209787354186","article-title":"The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: evidence for specific class-effects of antihypertensive drugs on pressure amplification","volume":"15","author":"Protogerou","year":"2009","journal-title":"Curr Pharm Des"},{"key":"2024012405585142000_CIT0024","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.amjhyper.2003.09.012","article-title":"Effect of different antihypertensive drug classes on central aortic pressure","volume":"17","author":"Morgan","year":"2004","journal-title":"Am J Hypertens"},{"key":"2024012405585142000_CIT0025","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"2024012405585142000_CIT0026","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2024012405585142000_CIT0027","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/jhh.2010.104","article-title":"Olmesartan\/amlodipine vs olmesartan\/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study","volume":"25","author":"Martinez-Martin","year":"2011","journal-title":"J Hum Hypertens"},{"key":"2024012405585142000_CIT0028","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12325-014-0117-9","article-title":"Open-label study assessing the long-term efficacy and safety of triple olmesartan\/amlodipine\/hydrochlorothiazide combination therapy for hypertension","volume":"31","author":"Volpe","year":"2014","journal-title":"Adv Ther"},{"key":"2024012405585142000_CIT0029","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00044011-200929070-00001","article-title":"Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study","volume":"29","author":"Barrios","year":"2009","journal-title":"Clin Drug Investig"},{"key":"2024012405585142000_CIT0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1475-2840-11-134","article-title":"Olmesartan\/amlodipine\/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study","volume":"11","author":"Kereiakes","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"2024012405585142000_CIT0031","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jash.2013.01.006","article-title":"Effect of a fixed combination of perindopril and amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: the AVANT\u2019AGE study","volume":"7","author":"Zhang","year":"2013","journal-title":"J Am Soc Hypertens"},{"key":"2024012405585142000_CIT0032","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jash.2015.01.012","article-title":"Efficacy and safety of perindopril arginine + amlodipine in hypertension","volume":"9","author":"Elliott","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"2024012405585142000_CIT0033","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/s12325-013-0076-6","article-title":"The fixed-dose combination of olmesartan\/amlodipine was superior in central aortic blood pressure reduction compared with perindopril\/amlodipine: a randomized, double-blind trial in patients with hypertension","volume":"30","author":"Ruilope","year":"2013","journal-title":"Adv Ther"},{"key":"2024012405585142000_CIT0034","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2024012405585142000_CIT0035","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"2024012405585142000_CIT0036","first-page":"499","article-title":"Pharmacokinetics of perindopril: therapeutic consequences","volume":"11","author":"Lees","year":"1989","journal-title":"Clin Exp Hypertens A"},{"key":"2024012405585142000_CIT0037","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.105.555235","article-title":"Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study","volume":"113","author":"Mattace-Raso","year":"2006","journal-title":"Circulation"},{"key":"2024012405585142000_CIT0038","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jash.2007.09.002","article-title":"Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease","volume":"2","author":"Franklin","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"2024012405585142000_CIT0039","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.hjh.0000160211.56103.48","article-title":"Benefits from angiotensin-converting enzyme inhibitor \u2018beyond blood pressure lowering\u2019: beyond blood pressure or beyond the brachial artery?","volume":"23","author":"Hirata","year":"2005","journal-title":"J Hypertens"},{"key":"2024012405585142000_CIT0040","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1097\/00004872-200212000-00022","article-title":"AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study","volume":"20","author":"Klingbeil","year":"2002","journal-title":"J Hypertens"},{"key":"2024012405585142000_CIT0041","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1291\/hypres.26.609","article-title":"Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients","volume":"26","author":"Takami","year":"2003","journal-title":"Hypertens Res"},{"key":"2024012405585142000_CIT0042","doi-asserted-by":"crossref","first-page":"H1567","DOI":"10.1152\/ajpheart.00622.2009","article-title":"Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension","volume":"297","author":"Lacolley","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024012405585142000_CIT0043","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/10641963.2014.960972","article-title":"Differential effects of angiotensin II receptor blocker and losartan\/hydrochlorothiazide combination on central blood pressure and augmentation index","volume":"37","author":"Metoki","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"2024012405585142000_CIT0044","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"2024012405585142000_CIT0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.ijcard.2012.04.155","article-title":"Measurement accuracy of non-invasively obtained central blood pressure by applanation tonometry: a systematic review and meta-analysis","volume":"167","author":"Cheng","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/9\/1055\/2622255","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/9\/1055\/2622255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T05:59:32Z","timestamp":1706075972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/9\/1055\/2622255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,5,24]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpw033","relation":{},"ISSN":["1941-7225","0895-7061"],"issn-type":[{"value":"1941-7225","type":"electronic"},{"value":"0895-7061","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,9]]},"published":{"date-parts":[[2016,5,24]]}}}